The cancer drug Abraxane (nab-paclitaxel) chalked up another weak showing in third quarter earnings for Celgene Corp., and Jacqualyn Fouse, global head of hematology and oncology, blamed the "big impact from the first wave" of immuno-oncology (I-O) therapies.